IL33 and neoplasm: Thus, the results of this study suggest that M2‐like macrophage differentiation is promoted by the elevated secretion of IL‐33 in the tumour sites via ODC activation during the establishment and progression of ESCC, and blocking IL‐33 or ODC may constitute a novel therapeutic route for patients with ESCC.